Reza Asari1, Oskar Koperek, Bruno Niederle. 1. Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria. reza.asari@meduniwien.ac.at
Abstract
BACKGROUND: The purpose of this study was to evaluate the frequency of malignancy, oncologic outcome and perioperative morbidity between small (≤60 mm) and large (>60 mm) adrenal tumors treated by endoscopic adrenalectomy (EA). METHODS: EA was performed in 289 consecutive patients with a mean follow-up of 87.7 ± 45.1 months. Patients were divided in those with tumor size ≤60 mm (group 1; n = 252) and >60 mm (group 2; n = 37). Data on patient's age, gender, hormone function, tumor side, operation time, postoperative complications, conversion to open approach, and rate of malignancy were analyzed. Furthermore, disease-free survival in malignant tumors was estimated and compared between both groups. RESULTS: Patient age (P = .43), gender (P = .09), tumor side (P = .17), and operative time (P = .33) showed no difference in both groups. Functioning tumors were observed in 85% of patients in group 1 compared with 46% in group 2 (P = .0001). Seven (2.8%) patients in group 1 and 7 (18.9%) in group 2 had malignant tumors (P = .0001). Neither rate of conversion (P = .71) and postoperative complication (P = .27) nor recurrence of malignancy (P = .48) differed between both groups. Estimated disease-free survival after 5 years in malignant lesions was 87.5 ± 11.7% for group 1 and 62.5 ± 21.3% for group 2 (P = .49). CONCLUSION: EA is a safe and feasible procedure in the majority of large adrenal tumors. Tumor size does not affect the outcome of surgery. In case of malignancy, it does not increase the rate of local recurrence. In experienced hands, tumor size should not influence the decision of surgical access (endoscopic versus open).
BACKGROUND: The purpose of this study was to evaluate the frequency of malignancy, oncologic outcome and perioperative morbidity between small (≤60 mm) and large (>60 mm) adrenal tumors treated by endoscopic adrenalectomy (EA). METHODS:EA was performed in 289 consecutive patients with a mean follow-up of 87.7 ± 45.1 months. Patients were divided in those with tumor size ≤60 mm (group 1; n = 252) and >60 mm (group 2; n = 37). Data on patient's age, gender, hormone function, tumor side, operation time, postoperative complications, conversion to open approach, and rate of malignancy were analyzed. Furthermore, disease-free survival in malignant tumors was estimated and compared between both groups. RESULTS:Patient age (P = .43), gender (P = .09), tumor side (P = .17), and operative time (P = .33) showed no difference in both groups. Functioning tumors were observed in 85% of patients in group 1 compared with 46% in group 2 (P = .0001). Seven (2.8%) patients in group 1 and 7 (18.9%) in group 2 had malignant tumors (P = .0001). Neither rate of conversion (P = .71) and postoperative complication (P = .27) nor recurrence of malignancy (P = .48) differed between both groups. Estimated disease-free survival after 5 years in malignant lesions was 87.5 ± 11.7% for group 1 and 62.5 ± 21.3% for group 2 (P = .49). CONCLUSION:EA is a safe and feasible procedure in the majority of large adrenal tumors. Tumor size does not affect the outcome of surgery. In case of malignancy, it does not increase the rate of local recurrence. In experienced hands, tumor size should not influence the decision of surgical access (endoscopic versus open).
Authors: Colleen M Kiernan; Myrick C Shinall; William Mendez; Mary F Peters; James T Broome; Carmen C Solorzano Journal: Am J Surg Date: 2014-07-25 Impact factor: 2.565
Authors: Barbara Kiesewetter; Philipp Riss; Christian Scheuba; Peter Mazal; Elisabeth Kretschmer-Chott; Alexander Haug; Markus Raderer Journal: Ther Adv Med Oncol Date: 2021-08-31 Impact factor: 5.485
Authors: James G Bittner; Victoria M Gershuni; Brent D Matthews; Jeffrey F Moley; L Michael Brunt Journal: Surg Endosc Date: 2013-02-13 Impact factor: 4.584
Authors: Carlo V Feo; Mattia Portinari; Umberto Maestroni; Paolo Del Rio; Silvia Severi; Lorenzo Viani; Riccardo Pravisani; Giorgio Soliani; Maria Chiara Zatelli; Maria Rosaria Ambrosio; Jenny Tong; Giovanni Terrosu; Vittorio Bresadola Journal: Surg Endosc Date: 2015-11-05 Impact factor: 4.584
Authors: Michał Pędziwiatr; Mateusz Wierdak; Michał Natkaniec; Maciej Matłok; Magdalena Białas; Piotr Major; Piotr Budzyński; Alicja Hubalewska-Dydejczyk; Andrzej Budzyński Journal: BMC Surg Date: 2015-08-28 Impact factor: 2.102
Authors: Nuri Alper Sahbaz; Ahmet Cem Dural; Cevher Akarsu; Deniz Guzey; Mehmet Kulus; Sema Ciftci Dogansen; Meral Mert; Halil Alis Journal: Wideochir Inne Tech Maloinwazyjne Date: 2019-05-15 Impact factor: 1.195